Table 1 Summary of individual clinical and genetic parameters and their combinations for the whole patient cohort

From: Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study

 

Pts

nrel

5y rel/progr.

nNRM

5y-NRM

5y-EFS

Death

5y-OS

p

Age at diagnosis

 <18 m

55

7

0.12 ± 0.05

2

0.04 ± 0.03

0.85 ± 0.05

6

0.90 ± 0.04

0.000

 >18 m

44

23

0.53 ± 0.08

4

0.09 ± 0.04

0.37 ± 0.08

25

0.36 ± 0.08

 

 p

  

<0.001

 

0.280

<0.001

   

INSS stage

 Stages 1, 2

28

2

0.07 ± 0.05

1

0.04 ± 0.04

0.89 ± 0.06

2

0.93 ± 0.05

0.000

 Stage 3

24

4

0.18 ± 0.08

2

0.08 ± 0.06

0.74 ± 0.09

4

0.83 ± 0.08

 

 Stage 4s

5

2

0.40 ± 0.22

0

0.00 ± 0.00

0.60 ± 0.22

1

0.75 ± 0.22

<

 Stage 4

41

22

0.52 ± 0.08

3

0.07 ± 0.04

0.41 ± 0.08

24

0.39 ± 0.08

 

 p

  

0.004

 

0.772

<0.001

   

Segmental chromosome aberrations

 NCA

15

0

0.00 ± 0.00

1

0.07 ± 0.07

0.93 ± 0.07

1

0.93 ± 0.07

0.016

 het typSCA

7

0

0.00 ± 0.00

0

0.00 ± 0.00

1.00 ± 0.00

0

1.00 ± 0.00

 

 typSCA

60

25

0.41 ± 0.07

6

0.10 ± 0.04

0.54 ± 0.07

23

0.59 ± 0.07

 

 p

  

<0.001

 

0.672

0.004

   

Tumour cell ploidy

 Aneuploid

59

14

0.24 ± 0.06

2

0.03 ± 0.02

0.73 ± 0.06

13

0.77 ± 0.06

 

 Diploid

22

12

0.52 ± 0.11

0

0.00

0.48 ± 0.11

11

0.47 ± 0.11

0.030

 Tetraploid

9

3

0.38 ± 0.17

2

0.22 ± 0.14

0.40 ± 0.17

4

0.44 ± 0.21

 

 p

  

0.039

 

0.012

0.024

   

Stage and age at diagnosis

 Localised <18 m

39

2

0.05 ± 0.04

2

0.05 ± 0.04

0.89 ± 0.05

2

0.95 ± 0.04

0.011

 Localised >18 m

13

4

0.34 ± 0.14

1

0.08 ± 0.07

0.59 ± 0.14

4

0.67 ± 0.14

 

 p

  

0.021

 

0.719

0.016

   

 Stage 4 <18 m

10

3

0.24 ± 0.15

0

0.00

0.76 ± 0.15

3

0.76 ± 0.15

0.084

 stage 4 >18 m

31

19

0.60 ± 0.09

3

0.10 ± 0.05

0.30 ± 0.09

21

0.28 ± 0.09

 

 p

  

0.211

 

<0.001

0.071

   

Segmental chromosome aberrations and age at diagnosis

 NCA <18 m

12

0

0.00 ± 0.00

1

0.08 ± 0.08

0.92 ± 0.08

1

0.92 ± 0.08

0.493

 het typSCA <18 m

7

0

0.00 ± 0.00

0

0.00 ± 0.00

1.00 ± 0.00

0

1.00 ± 0.00

 

 typSCA <18 m

26

6

0.21 ± 0.08

1

0.04 ± 0.04

0.75 ± 0.09

4

0.88 ± 0.07

 

 p

  

<0.001

 

0.326

0.166

   

 NCA >18 m

3

0

0.00 ± 0.00

0

0.00 ± 0.00

1.00 ± 0.00

0

1.00 ± 0.00

0.156

 typSCA >18 m

34

19

0.55 ± 0.09

2

0.06 ± 0.04

0.39 ± 0.09

19

0.36 ± 0.09

 

 p

  

NA

 

NA

NA

   

Tumour cell ploidy and age at diagnosis

 Aneuploid <18 m

42

5

0.10 ± 0.05

2

0.05 ± 0.03

0.85 ± 0.06

4

0.93 ± 0.04

 

 Diploid <18 m

5

1

0.25 ± 0.22

0

0.00 ± 0.00

0.75 ± 0.22

1

0.75 ± 0.22

0.430

 Tetraploid <18 m

4

1

0.25 ± 0.22

0

0.00 ± 0.00

0.75 ± 0.22

1

0.75 ± 0.22

 

 p

  

0.560 (NA)

 

NA

0.831

   

 Aneuploid >18 m

17

9

0.62 ± 0.13

0

0.00

0.38 ± 0.13

9

0.34 ± 0.13

 

 Diploid >18 m

17

11

0.59 ± 0.12

0

0.00

0.41 ± 0.12

10

0.40 ± 0.12

0.742

 Tetraploid >18 m

5

2

0.40 ± 0.22

2

0.40 ± 0.22

0.20 ± 0.18

3

0.60 ± 0.22

 

 p

  

0.694

 

NA

0.326

   

Segmental chromosome aberrations, stage and age at diagnosis

 NCA, localised <18 m

11

0

0.00 ± 0.00

1

0.09 ± 0.09

0.91 ± 0.09

1

0.91 ± 0.09

0.773

 het typSCA, localised <18 m

6

0

0.00 ± 0.00

0

0.00 ± 0.00

1.00 ± 0.00

0

1.00 ± 0.00

 

 typSCA, localised <18 m

14

2

0.14 ± 0.09

1

0.07 ± 0.07

0.79 ± 0.11

1

0.93 ± 0.07

 

 p

  

<0.001

 

NA

0.394

   

 NCA, localised >18 m

2

0

0.00 ± 0.00

0

0.00 ± 0.00

1.00 ± 0.00

0

1.00 ± 0.00

0.447

 typSCA, localised >18 m

10

4

0.40 ± 0.15

1

0.10 ± 0.09

0.50 ± 0.16

4

0.60 ± 0.15

 

 p

  

NA

 

NA

NA

   

 typSCA, stage 4 <18 m

9

2

0.13 ± 0.12

0

0.00 ± 0.00

0.88 ± 0.12

2

0.88 ± 0.12

 

 p

 NCA, stage 4 >18 m

1

0

 

0

  

0

  

 typSCA, stage 4 >18 m

24

15

0.59 ± 0.10

1

0.04 ± 0.04

0.36 ± 0.10

15

0.32 ± 0.10

 

 p

  

NA

 

NA

NA

   

Tumour cell ploidy, stage and age at diagnosis

 Aneuploid, localised <18 m

35

2

0.06 ± 0.04

2

0.06 ± 0.04

0.88 ± 0.06

2

0.94 ± 0.04

 

 Diploid, localised <18 m

2

0

 

0

  

0

1.00 ± 0.00

0.731

 p

  

NA

 

NA

NA

   

 Aneuploid, localised >18 m

8

3

0.43 ± 0.19

0

0.00 ± 0.00

0.57 ± 0.19

3

0.57 ± 0.19

 

 Diploid, localised >18 m

2

0

 

0

  

0

1.00 ± 0.00

0.500

 Tetraploid, localised >18 m

2

1

0.50 ± 0.35

1

0.50 ± 0.35

0.00 ± 0.00

1

0.50 ± 0.35

 

 p

  

NA

 

NA

NA

   

 Aneuploid, stage 4 <18 m

4

1

0.00 ± 0.00

0

0.00 ± 0.00

1.00 ± 0.00

1

1.00 ± 00

NA

 Diploid, stage 4 <18 m

3

1

0.50 ± 0.35

0

0.00 ± 0.00

0.50 ± 0.35

1

0.50 ± 0.35

 

 Tetraploid, stage 4 <18 m

2

1

0.50 ± 0.35

0

0.00 ± 0.00

0.50 ± 0.35

1

0.50 ± 0.35

 

 p

  

NA

 

NA

NA

   

 Aneuploid, stage 4 >18 m

9

6

0.70 ± 0.16

0

0.00

0.30 ± 0.16

6

0.26 ± 0.16

0.992

 Diploid, stage 4 >18 m

15

11

0.67 ± 0.12

0

0.00

0.33 ± 0.12

10

0.31 ± 0.12

 

 Tetraploid, stage 4 >18 m

3

1

0.33 ± 0.27

1

0.33 ± 0.27

0.33 ± 0.27

1

0.67 ± 0.27

 

 p

  

0.588

 

NA

0.867

   
  1. Statistic results for 5-year relapse frequencies, non-relapse mortality, 5-year event-free and overall survival in the individual age and INSS stage subgroups as well as the genomic subgroups (segmental chromosome aberrations and ploidy) and their combinations. Stage 4s tumours are not included because of small case numbers
  2. Statistically significant (<0.05) p-values are indicated in bold. atyp atypical, EFS event-free survival, pts patients, n number, het heterogeneous, INSS International Neuroblastoma Staging System, NA not applicable, NCA numerical chromosome aberrations only, NRM non-relapse mortality, OS overall survival, p p-value, progr. progression, rel relapses, SCA segmental chromosome aberrations, typ typical, y year
Back to article page